Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Dongseong | - |
dc.contributor.author | Lee, SeungHwan | - |
dc.contributor.author | Yi, Sojeong | - |
dc.contributor.author | Yoon, Seo Hyun | - |
dc.contributor.author | Cho, Joo-Youn | - |
dc.contributor.author | Bahng, Mi Young | - |
dc.contributor.author | Jang, In-Jin | - |
dc.contributor.author | Yu, Kyung-Sang | - |
dc.date.available | 2020-02-27T23:42:35Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1177-8881 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7547 | - |
dc.description.abstract | Objective: DA-8031 is a selective serotonin reuptake inhibitor under development for the treatment of premature ejaculation. This is the first- in- human study aimed at evaluating the pharmacokinetics and tolerability of DA-8031 and its metabolites (M1, M2, M4, and M5) in the plasma and urine after administration of a single oral dose in healthy male subjects. Methods: A dose block-randomized, double-blind, placebo-controlled, single ascending dose study was conducted. Subjects received either placebo or a single dose of DA-8031 at 5, 10, 20, 40, 60, 80, or 120 mg. DA-8031 and its four metabolites were analyzed in the plasma and urine for pharmacokinetic evaluation. The effect of genetic polymorphisms of cytochrome-P450 (CYP) enzymes on the pharmacokinetics of DA-8031 was evaluated. Results: After a single dose, plasma DA-8031 reached the maximum concentration at a median of 2-3 h and was eliminated with terminal elimination half-life of 17.9-28.7 h. The mean renal clearance was 3.7- 5.6 L/h. Dose-proportional pharmacokinetics was observed over the dose range of 20-80 mg. Among the metabolites, M4 had the greatest plasma concentration, followed by M5 and M1. Subjects with CYP2D6 intermediate metabolizer had significantly greater dose-normalized C-max and AUC(0-t) of DA-8031 as well as smaller metabolic ratios than those subjects with CYP2D6 extensive metabolizer. The most common adverse events were nausea, dizziness, and headache, and no serious adverse events were reported. Conclusion: In conclusion, the systemic exposure of DA-8031 was increased proportionally to the dose within 20-80 mg. Genetic polymorphisms of CYP2D6 had an effect on the systemic exposure of DA-8031. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.relation.isPartOf | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.subject | SEXUALITY SURVEY GOSS | - |
dc.subject | INTERNATIONAL-SOCIETY | - |
dc.subject | QTC PROLONGATION | - |
dc.subject | INTERNET USERS | - |
dc.subject | DE-POINTES | - |
dc.subject | PREVALENCE | - |
dc.subject | METABOLISM | - |
dc.subject | GUIDELINES | - |
dc.subject | INTERVAL | - |
dc.title | Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000395899100001 | - |
dc.identifier.doi | 10.2147/DDDT.S126861 | - |
dc.identifier.bibliographicCitation | DRUG DESIGN DEVELOPMENT AND THERAPY, v.11, pp.713 - 723 | - |
dc.identifier.scopusid | 2-s2.0-85015306497 | - |
dc.citation.endPage | 723 | - |
dc.citation.startPage | 713 | - |
dc.citation.title | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.citation.volume | 11 | - |
dc.contributor.affiliatedAuthor | Shin, Dongseong | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | DA-8031 | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | selective serotonin reuptake inhibitor | - |
dc.subject.keywordAuthor | premature ejaculation | - |
dc.subject.keywordAuthor | first in human | - |
dc.subject.keywordPlus | SEXUALITY SURVEY GOSS | - |
dc.subject.keywordPlus | INTERNATIONAL-SOCIETY | - |
dc.subject.keywordPlus | QTC PROLONGATION | - |
dc.subject.keywordPlus | INTERNET USERS | - |
dc.subject.keywordPlus | DE-POINTES | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | METABOLISM | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | INTERVAL | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.